Keith Wayne Ward - Dec 14, 2021 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Stock symbol
SKYE
Transactions as of
Dec 14, 2021
Transactions value $
$0
Form type
4
Date filed
12/16/2021, 05:50 PM
Next filing
Jan 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Director Option Grant (Right to Buy) Award $0 +250K $0.00 250K Dec 14, 2021 Common Stock 250K $0.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option grant shall be exercisable for a price of $0.058 per Option Share for ten years from December 14, 2021 (the "Grant Date") and the Options will vest in equal monthly installments over the one year period from the Grant Date.